Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces the departure of Messrs. Victor Neufeld and Dennis Staudt, respectively, as Directors of the Company (“Board”), effective immediately. The Company expresses its appreciation for Mr. Neufeld and Mr. Staudt’s services to the Company and wishes them the very best.
Stated Mr. Neufeld, “Both Dennis and myself have enjoyed our tenure on the Board, assisting and mentoring the HAVN strategic vision as the Company pursued opportunities in the psychedelic and functional mushroom sectors. Our Board resignations reflect other personal commitments, but we remain supportive long term shareholders.”
The Company is pleased to announce that Mr. Tim Moore, Chief Executive Officer and Director, has been appointed Chairman of the Board, and that Mr. Gordon Clissold, the Company’s Chief Financial Officer, has been appointed as a Director.
On Behalf of The Board of Directors
About HAVN Life Sciences Inc.
HAVN Life Sciences Inc. is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.
Investor Relations: firstname.lastname@example.org 604 359 0060
Media: email@example.com 647 896-8078
The CSE has not reviewed, approved or disapproved the content of this press release